Bolt Biotherapeutics, Inc. Impaired Financing Receivable, Related Allowance
Bolt Biotherapeutics, Inc. (BOLT) had Impaired Financing Receivable, Related Allowance of $0 as of 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Notes
us-gaap:ImpairedFinancingReceivableRelatedAllowance · last filed 2024-05-14
- 2024-03-31: Impaired Financing Receivable, Related Allowance $0.00.
- 2023-12-31: Impaired Financing Receivable, Related Allowance $0.00.
- 2023-09-30: Impaired Financing Receivable, Related Allowance $0.00.
- 2023-06-30: Impaired Financing Receivable, Related Allowance $0.00.
| Period end | Impaired Financing Receivable, Related Allowance |
|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 |
| 2023-12-31 | $0.00 10-K · filed 2024-03-21 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-07 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |